Actieve functies van Geoffrey Harris
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Ocelot Bio, Inc.
Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | Directeur/Bestuurslid | - | - |
Financieel Directeur/CFO | - | - | |
Oprichter | - | - | |
Bedrijfssecretaris | - | - | |
Algemeen Directeur | - | 23-03-2022 | |
President | - | 23-03-2022 |
Loopbaan van Geoffrey Harris
Statistieken
Internationaal
Verenigde Staten | 2 |
Operationeel
Director/Board Member | 1 |
Chief Executive Officer | 1 |
Director of Finance/CFO | 1 |
Sectoraal
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Ocelot Bio, Inc.
Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | Health Technology |
- Beurs
- Insiders
- Geoffrey Harris
- Ervaring